Retaspimycin: Preliminary Phase I/II data

Preliminary data from the Phase II portion of an ongoing, open-label, U.S. Phase I/II trial (IPI-504-03) in 28 patients with wild-type epidermal growth factor receptor (EGFR) expression showed that I...